Burnaby, BC, December 16, 2020--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced updates on its proprietary and partnered neurology programs at AES2020, the virtual Annual Meeting of the American Epilepsy Society.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 50-99 Employees In BC (50-99 Employees Total)
Founded: 1987 | Revenues: $15.60 Million
XENON® (NASDAQ: XENE) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform.
Burnaby, BC, October 9, 2020--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a neurology-focused biopharmaceutical company, provided regulatory updates on its proprietary pediatric neurology program, XEN496, a Kv7 potassium channel modulator that is a proprietary pediatric formulation of the active ingredient ezogabine being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE).
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 50-99 Employees In BC (50-99 Employees Total)
Founded: 1987 | Revenues: $15.60 Million
XENON® (NASDAQ: XENE) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform.
Burnaby, BC, August 25, 2020--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced the appointment of Dr. Chris Von Seggern as Chief Commercial Officer, effective immediately.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 50-99 Employees In BC (50-99 Employees Total)
Founded: 1987 | Revenues: $15.60 Million
XENON® (NASDAQ: XENE) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform.
Burnaby, BC, August 13, 2020--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a neurology-focused biopharmaceutical company, reported its financial results for second quarter ended June 30, 2020 and provided a corporate update.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 50-99 Employees In BC (50-99 Employees Total)
Founded: 1987 | Revenues: $15.60 Million
XENON® (NASDAQ: XENE) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform.
Burnaby, BC, May 28, 2020--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a neurology-focused biopharmaceutical company, reported its financial results for first quarter ended March 31, 2020 and provided a corporate update.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 50-99 Employees In BC (50-99 Employees Total)
Founded: 1987 | Revenues: $15.60 Million
XENON® (NASDAQ: XENE) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform.
Burnaby, BC, March 31, 2020--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a clinical stage biopharmaceutical company, announced equity inducement grants to eight new non-officer employees consisting of an aggregate of 63,200 share options.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 50-99 Employees In BC (50-99 Employees Total)
Founded: 1987 | Revenues: $15.60 Million
XENON® (NASDAQ: XENE) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform.
Burnaby, BC, March 9, 2020--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a clinical stage biopharmaceutical company, reported its financial results for the year ended December 31, 2019 and provided a corporate update.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 50-99 Employees In BC (50-99 Employees Total)
Founded: 1987 | Revenues: $15.60 Million
XENON® (NASDAQ: XENE) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform.
Burnaby, BC, January 15, 2020--enon Pharmaceuticals Inc.(Nasdaq:XENE), a clinical stage biopharmaceutical company, provided a corporate update and outlined its key milestone opportunities for 2020.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 50-99 Employees In BC (50-99 Employees Total)
Founded: 1987 | Revenues: $15.60 Million
XENON® (NASDAQ: XENE) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform.
Burnaby, BC, December 12, 2019--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a clinical stage biopharmaceutical company, announced that it will provide updates on its proprietary, neurology programs at the American Epilepsy Society (AES) Annual Meeting held in Baltimore, MD.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 50-99 Employees In BC (50-99 Employees Total)
Founded: 1987 | Revenues: $15.60 Million
XENON® (NASDAQ: XENE) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform.
Burnaby, BC, December 4, 2019--Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and (Nasdaq: XENE) announced a monster license and collaboration agreement to develop first-in-class treatments for epilepsy.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 50-99 Employees In BC (50-99 Employees Total)
Founded: 1987 | Revenues: $15.60 Million
XENON® (NASDAQ: XENE) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform.